SCHEMBL20683056

SCHEMBL20683056

C=C(OCC)c1cc2c(cn1)C(NC(=O)OC(C)(C)C)CCCC2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 4/20 0.36
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
TSHR P16473 1/20 0.34
ALDH1A1 P00352 5/20 0.34
HPGD P15428 5/20 0.34
KDM4E B2RXH2 4/20 0.34
CYP2D6 P10635 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
CYP3A4 P08684 2/20 0.34
CYP2C19 P33261 2/20 0.34
CNR2 P34972 3/20 0.34
CYP1A2 P05177 2/20 0.34
PKM P14618 1/20 0.34
LMNA P02545 2/20 0.33
CYP2C9 P11712 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
JAK2 O60674 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29766403 1.00 BTK (0.36) BTKCYP11B1CYP11B2TSHRALDH1A1
SCHEMBL20533179 0.88 TSHR (0.38) BTKTSHRALDH1A1HPGDKDM4E
SCHEMBL20683066 0.85 BTK (0.39) BTKTSHRALDH1A1CYP3A4CNR2
SCHEMBL29766427 0.85 BTK (0.39) BTKTSHRALDH1A1CYP3A4CNR2
SCHEMBL26073296 0.83 BTK (0.35) BTKTSHRALDH1A1CYP3A4CNR2
SCHEMBL20683042 0.80 KMT2A (0.34) BTKALDH1A1HPGDKDM4ECYP2D6
SCHEMBL29766231 0.78 BTK (0.34) BTKALDH1A1CYP3A4CNR2CYP2C9
SCHEMBL25489102 0.78 BTK (0.34) BTKALDH1A1CYP3A4CNR2CYP2C9
SCHEMBL26073300 0.78 BTK (0.34) BTKALDH1A1CYP3A4CNR2CYP2C9
SCHEMBL30522345 0.75 BTK (0.34) BTKBDKRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11858926-B2 Inhibiting agents for bruton's tyrosine kinase BIOGEN MA INC. (US) 2024-01-02 US disclosed
US-11858926-B2 Inhibiting agents for bruton's tyrosine kinase BIOGEN MA INC. (US) 2024-01-02 US disclosed
EP-4249071-A2 BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE Biogen MA Inc. (US) 2023-09-27 EP disclosed
US-20230147490-A1 INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE BIOGEN MA INC. 2023-05-11 US disclosed
US-20230147490-A1 INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE BIOGEN MA INC. 2023-05-11 US disclosed
US-11427577-B2 Inhibiting agents for Bruton's tyrosine kinase BIOGEN MA INC. (US) 2022-08-30 US disclosed
US-20210340135-A1 INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE BIOGEN MA INC. 2021-11-04 US disclosed
US-10961237-B2 Inhibiting agents for Bruton's tyrosine kinase BIOGEN MA INC. (US) 2021-03-30 US disclosed
US-20200239459-A1 INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE BIOGEN MA INC. 2020-07-30 US disclosed
CN-110621670-A Benzazepine analogs as inhibitors of bruton's tyrosine kinase 比奥根MA公司 2019-12-27 CN disclosed
US-10227341-B2 Inhibiting agents for bruton's tyrosine kinase BIOGEN MA INC. (US) 2019-03-12 US disclosed
US-10189829-B2 Inhibiting agents for Bruton's tyrosine kinase BIOGEN MA INC. (US) 2019-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10227341-B2 Inhibiting agents for bruton's tyrosine kinase ABL1, BTK, LYN BTK 2/4885CYP11B1 1689/4885CYP11B2 1727/4885
US-10961237-B2 Inhibiting agents for Bruton's tyrosine kinase ABL1, BTK, LYN BTK 2/4885CYP11B1 1689/4885CYP11B2 1727/4885
US-20210340135-A1 INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE ABL1, BTK, LYN BTK 2/4885CYP11B1 1689/4885CYP11B2 1727/4885
US-20200239459-A1 INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE ABL1, BTK, LYN BTK 2/4885CYP11B1 1689/4885CYP11B2 1727/4885
US-11427577-B2 Inhibiting agents for Bruton's tyrosine kinase ABL1, BTK, LYN BTK 2/4885CYP11B1 1689/4885CYP11B2 1727/4885
US-10189829-B2 Inhibiting agents for Bruton's tyrosine kinase ABL1, BTK, LYN BTK 2/4885CYP11B1 1689/4885CYP11B2 1727/4885
US-11858926-B2 Inhibiting agents for bruton's tyrosine kinase ABL1, BTK, LYN BTK 2/4885CYP11B1 1689/4885CYP11B2 1727/4885
US-20230147490-A1 INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE ABL1, BTK, LYN BTK 2/4885CYP11B1 1689/4885CYP11B2 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.